Logo image of ANGO

ANGIODYNAMICS INC (ANGO) Stock Fundamental Analysis

NASDAQ:ANGO - Nasdaq - US03475V1017 - Common Stock - Currency: USD

9.25  -0.27 (-2.84%)

After market: 9.25 0 (0%)

Fundamental Rating

2

Taking everything into account, ANGO scores 2 out of 10 in our fundamental rating. ANGO was compared to 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of ANGO have multiple concerns. ANGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ANGO had negative earnings in the past year.
ANGO had a negative operating cash flow in the past year.
In the past 5 years ANGO always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: ANGO reported negative operating cash flow in multiple years.
ANGO Yearly Net Income VS EBIT VS OCF VS FCFANGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M -150M

1.2 Ratios

ANGO has a Return On Assets (-14.50%) which is comparable to the rest of the industry.
ANGO's Return On Equity of -22.27% is fine compared to the rest of the industry. ANGO outperforms 60.73% of its industry peers.
Industry RankSector Rank
ROA -14.5%
ROE -22.27%
ROIC N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A
ANGO Yearly ROA, ROE, ROICANGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

ANGO has a Gross Margin of 54.36%. This is comparable to the rest of the industry: ANGO outperforms 47.12% of its industry peers.
ANGO's Gross Margin has declined in the last couple of years.
ANGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%
ANGO Yearly Profit, Operating, Gross MarginsANGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

ANGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANGO has more shares outstanding
Compared to 5 years ago, ANGO has more shares outstanding
There is no outstanding debt for ANGO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ANGO Yearly Shares OutstandingANGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ANGO Yearly Total Debt VS Total AssetsANGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ANGO has an Altman-Z score of 1.33. This is a bad value and indicates that ANGO is not financially healthy and even has some risk of bankruptcy.
ANGO's Altman-Z score of 1.33 is in line compared to the rest of the industry. ANGO outperforms 58.12% of its industry peers.
ANGO has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.03, ANGO is in the better half of the industry, outperforming 64.92% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.33
ROIC/WACCN/A
WACC9%
ANGO Yearly LT Debt VS Equity VS FCFANGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.21 indicates that ANGO has no problem at all paying its short term obligations.
ANGO has a Current ratio (2.21) which is in line with its industry peers.
ANGO has a Quick Ratio of 1.40. This is a normal value and indicates that ANGO is financially healthy and should not expect problems in meeting its short term obligations.
ANGO has a worse Quick ratio (1.40) than 64.92% of its industry peers.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 1.4
ANGO Yearly Current Assets VS Current LiabilitesANGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 41.94% over the past year.
ANGO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.56%.
Measured over the past years, ANGO shows a small growth in Revenue. The Revenue has been growing by 2.35% on average per year.
EPS 1Y (TTM)41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.75%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-4.23%

3.2 Future

Based on estimates for the next years, ANGO will show a very strong growth in Earnings Per Share. The EPS will grow by 27.82% on average per year.
Based on estimates for the next years, ANGO will show a small growth in Revenue. The Revenue will grow by 5.85% on average per year.
EPS Next Y24.15%
EPS Next 2Y18.62%
EPS Next 3Y30.75%
EPS Next 5Y27.82%
Revenue Next Year-2.08%
Revenue Next 2Y2.05%
Revenue Next 3Y3.79%
Revenue Next 5Y5.85%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ANGO Yearly Revenue VS EstimatesANGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 100M 200M 300M
ANGO Yearly EPS VS EstimatesANGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.2 -0.2 0.4 -0.4 0.6 0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ANGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGO Price Earnings VS Forward Price EarningsANGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

62.30% of the companies in the same industry are more expensive than ANGO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7105.04
ANGO Per share dataANGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as ANGO's earnings are expected to grow with 30.75% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.62%
EPS Next 3Y30.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGIODYNAMICS INC

NASDAQ:ANGO (4/21/2025, 4:05:09 PM)

After market: 9.25 0 (0%)

9.25

-0.27 (-2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-02 2025-04-02/bmo
Earnings (Next)07-14 2025-07-14/amc
Inst Owners83.14%
Inst Owner Change-0.11%
Ins Owners5.35%
Ins Owner Change1.81%
Market Cap375.64M
Analysts84.44
Price Target15.64 (69.08%)
Short Float %4.49%
Short Ratio2.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)93.49%
Min EPS beat(2)64.35%
Max EPS beat(2)122.62%
EPS beat(4)4
Avg EPS beat(4)69.54%
Min EPS beat(4)26.47%
Max EPS beat(4)122.62%
EPS beat(8)6
Avg EPS beat(8)36.68%
EPS beat(12)8
Avg EPS beat(12)5.72%
EPS beat(16)11
Avg EPS beat(16)5.43%
Revenue beat(2)2
Avg Revenue beat(2)0.55%
Min Revenue beat(2)0.41%
Max Revenue beat(2)0.68%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-2.6%
Max Revenue beat(4)0.68%
Revenue beat(8)2
Avg Revenue beat(8)-1.72%
Revenue beat(12)3
Avg Revenue beat(12)-1.75%
Revenue beat(16)5
Avg Revenue beat(16)-1.13%
PT rev (1m)0%
PT rev (3m)17.95%
EPS NQ rev (1m)-33.33%
EPS NQ rev (3m)-63.64%
EPS NY rev (1m)21.62%
EPS NY rev (3m)27.5%
Revenue NQ rev (1m)0.25%
Revenue NQ rev (3m)-0.59%
Revenue NY rev (1m)0.61%
Revenue NY rev (3m)0.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B 2.02
P/tB 3.27
EV/EBITDA 7105.04
EPS(TTM)-0.18
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS6.98
BVpS4.58
TBVpS2.83
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.5%
ROE -22.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.36%
FCFM N/A
ROA(3y)-24.22%
ROA(5y)-21.27%
ROE(3y)-36.59%
ROE(5y)-30.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.88%
GM growth 5Y-2.46%
F-Score4
Asset Turnover0.99
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 120.41
Cap/Depr 15.88%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 1.4
Altman-Z 1.33
F-Score4
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)16.52%
Cap/Depr(5y)20.29%
Cap/Sales(3y)1.51%
Cap/Sales(5y)1.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%118.75%
EPS Next Y24.15%
EPS Next 2Y18.62%
EPS Next 3Y30.75%
EPS Next 5Y27.82%
Revenue 1Y (TTM)-12.56%
Revenue growth 3Y1.46%
Revenue growth 5Y2.35%
Sales Q2Q%-4.23%
Revenue Next Year-2.08%
Revenue Next 2Y2.05%
Revenue Next 3Y3.79%
Revenue Next 5Y5.85%
EBIT growth 1Y13.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year107.33%
EBIT Next 3Y46.49%
EBIT Next 5Y34.24%
FCF growth 1Y-141.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-227.02%
OCF growth 3YN/A
OCF growth 5YN/A